Arcturus Therapeutics Holdings annual ebitda
2018
2019
2020
2021
2022
2023
2024
2025
Arcturus Therapeutics Holdings EBITDA Growth & History (ARCT)
Arcturus Therapeutics Holdings's calculated EBITDA was −$73.2M for fiscal 2025.
View full Arcturus Therapeutics Holdings company overviewArcturus Therapeutics Holdings annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$73.2M | $18.9M | — |
| 2024 | 2024-12-31 | −$92.1M | −$16.9M | — |
| 2023 | 2023-12-31 | −$75.2M | −$89.0M | — |
| 2022 | 2022-12-31 | $13.7M | $215.4M | — |
| 2021 | 2021-12-31 | −$201.7M | −$131.0M | — |
| 2020 | 2020-12-31 | −$70.6M | −$45.8M | — |
| 2019 | 2019-12-31 | −$24.8M | −$3.6M | — |
| 2018 | 2018-12-31 | −$21.2M | — | — |
Arcturus Therapeutics Holdings quarterly ebitda
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$24.9M | −$14.1M | — |
| Q1 2026 | 2026-03-31 | −$28.3M | −$12.2M | — |
| Q4 2025 | 2025-12-31 | −$30.7M | $1.9M | — |
| Q3 2025 | 2025-09-30 | −$15.7M | −$5.9M | — |
| Q2 2025 | 2025-06-30 | −$10.8M | $9.4M | — |
| Q1 2025 | 2025-03-31 | −$16.0M | $13.5M | — |
| Q4 2024 | 2024-12-31 | −$32.6M | −$15.2M | — |
| Q3 2024 | 2024-09-30 | −$9.8M | $8.7M | — |
| Q2 2024 | 2024-06-30 | −$20.2M | $34.4M | — |
| Q1 2024 | 2024-03-31 | −$29.5M | −$44.8M | — |
| Q4 2023 | 2023-12-31 | −$17.4M | −$139.3M | — |
| Q3 2023 | 2023-09-30 | −$18.5M | $17.9M | — |
| Q2 2023 | 2023-06-30 | −$54.7M | −$33.0M | — |
| Q1 2023 | 2023-03-31 | $15.3M | $65.5M | — |
| Q4 2022 | 2022-12-31 | $122.0M | $159.3M | — |
| Q3 2022 | 2022-09-30 | −$36.4M | $17.1M | — |
| Q2 2022 | 2022-06-30 | −$21.7M | $31.7M | — |
| Q1 2022 | 2022-03-31 | −$50.2M | $7.2M | — |
| Q4 2021 | 2021-12-31 | −$37.4M | −$6.6M | — |
| Q3 2021 | 2021-09-30 | −$53.5M | −$32.8M | — |
| Q2 2021 | 2021-06-30 | −$53.4M | −$43.6M | — |
| Q1 2021 | 2021-03-31 | −$57.4M | −$48.1M | — |
| Q4 2020 | 2020-12-31 | −$30.8M | −$20.1M | — |
| Q3 2020 | 2020-09-30 | −$20.7M | −$13.3M | — |
| Q2 2020 | 2020-06-30 | −$9.8M | −$9.5M | — |
| Q1 2020 | 2020-03-31 | −$9.3M | −$2.9M | — |
| Q4 2019 | 2019-12-31 | −$10.7M | — | — |
| Q3 2019 | 2019-09-30 | −$7.4M | −$3.3M | — |
| Q2 2019 | 2019-06-30 | −$372,000 | $9.6M | — |
| Q1 2019 | 2019-03-31 | −$6.3M | — | — |
| Q3 2018 | 2018-09-30 | −$4.2M | — | — |
| Q2 2018 | 2018-06-30 | −$10.0M | — | — |
Arcturus Therapeutics Holdings ebitda trends
Over the last five fiscal years, Arcturus Therapeutics Holdings's ebitda decreased from −$70.6M to −$73.2M, a change of −$2.6M. The latest reported quarter, Q2 2026, shows −$24.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcturus Therapeutics Holdings source filings ↗